Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1976 May 15;1(6019):1186–1188. doi: 10.1136/bmj.1.6019.1186

Effects of methyldopa on prolactin and growth hormone.

J Steiner, J Cassar, K Mashiter, I Dawes, T R Fraser, A Breckenridge
PMCID: PMC1639736  PMID: 1268617

Abstract

The effects of administration of methyldopa on serum prolactin and growth hormone (GH) concentrations in hypertensive patients were studied. Single doses of methyldopa (750 or 1000 mg) significantly increased serum prolactin levels, peak concentrations occurring four to six hours after drug administrations. Long-term methyldopa treatment was associated with threefold to fourfold increases in basal prolactin levels compared with those in normal subjects. In patients treated with methyldopa for two to three weeks the GH response to insulin hypoglycaemia was significantly greater than in normal subjects and untreated hypertensive patients. In contrast, patients treated for prolonged periods (mean 13-4 months) had a GH reponse indistinguishable from normal.

Full text

PDF
1186

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackard W. G., Hubbell G. J. Stimulatory effect of exogenous catecholamines on plasma HGH concentrations in presence of beta adrenergic blockade. Metabolism. 1970 Jul;19(7):547–552. doi: 10.1016/0026-0495(70)90010-7. [DOI] [PubMed] [Google Scholar]
  2. Bryant E. E., Douglas B. H., Ashburn A. D. The effect of prolactin on blood pressure, blood volume, and angiotensin response. J Lab Clin Med. 1971 Nov;78(5):795–796. [PubMed] [Google Scholar]
  3. Finch L., Haeusler G. Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat. Br J Pharmacol. 1973 Feb;47(2):217–228. doi: 10.1111/j.1476-5381.1973.tb08319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. HARTOG M., GAAFAR M. A., MEISSER B., FRASER R. IMMUNOASSAY OF SERUM GROWTH HORMONE IN ACROMEGALIC PATIENTS. Br Med J. 1964 Nov 14;2(5419):1229–1232. doi: 10.1136/bmj.2.5419.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Horrobin D. F., Lloyd I. J., Lipton A., Burstyn P. G., Durkin N., Muiruri K. L. Actions of prolactin on human renal function. Lancet. 1971 Aug 14;2(7720):352–354. doi: 10.1016/s0140-6736(71)90065-1. [DOI] [PubMed] [Google Scholar]
  6. Horrobin D. F., Manku M. S., Burstyn P. G. Effect of intravenous prolactin infusion on arterial blood pressure in rabbits. Cardiovasc Res. 1973 Sep;7(5):585–587. doi: 10.1093/cvr/7.5.585. [DOI] [PubMed] [Google Scholar]
  7. Kobinger W., Walland A. Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl. Eur J Pharmacol. 1967 Dec;2(3):155–162. doi: 10.1016/0014-2999(67)90080-5. [DOI] [PubMed] [Google Scholar]
  8. Laverty R., Taylor K. M. The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique. Anal Biochem. 1968 Feb;22(2):269–279. doi: 10.1016/0003-2697(68)90316-3. [DOI] [PubMed] [Google Scholar]
  9. MacLeod R. M. Influence of norepinephrine and catecholamine-depleting agents on the synthesis and release of prolactin and growth hormone. Endocrinology. 1969 Nov;85(5):916–923. doi: 10.1210/endo-85-5-916. [DOI] [PubMed] [Google Scholar]
  10. Sirtori C. R., Bolme P., Azarnoff D. L. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med. 1972 Oct 12;287(15):729–733. doi: 10.1056/NEJM197210122871501. [DOI] [PubMed] [Google Scholar]
  11. Turkington R. W. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med. 1972 Sep;130(3):349–354. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES